SBIA
TOVX icon

Sheaff Brock Investment Advisors’s Theriva Biologics TOVX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11
Closed -$24K – 557
2018
Q2 		$24K Hold
11
– – ﹤0.01% 536
2018
Q1 		$32K Hold
11
– – ﹤0.01% 542
2017
Q4 		$51K Sell
11
-5
-31% -$31.2K 0.01% 515
2017
Q3 		$131K Hold
16
– – 0.02% 525
2017
Q2 		$79K Buy
16
+1
+7% +$4.98K 0.01% 579
2017
Q1 		$82K Buy
15
+4
+36% +$27.9K 0.01% 569
2016
Q4 		$76K Buy
11
+1
+10% +$10.3K 0.01% 581
2016
Q3 		$149K Hold
10
– – 0.02% 493
2016
Q2 		$156K Buy
10
+2
+25% +$37.6K 0.02% 515
2016
Q1 		$167K Sell
8
-2
-20% -$30.1K 0.02% 514
2015
Q4 		$195K Buy
+10
New +$212K 0.02% 517

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Sheaff Brock Investment Advisors's TOVX Position: Q3 2018 in Review

Sheaff Brock Investment Advisors sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 11 shares — an estimated $24K sold.

Sheaff Brock Investment Advisors first reported a position in TOVX in Q4 2015 and held it in 11 quarters. The position peaked at $195K in Q4 2015. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

  • Sheaff Brock Investment Advisors reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 11 Theriva Biologics shares in Q3 2018, an estimated $24K.
  • Sheaff Brock Investment Advisors first reported a position in Theriva Biologics in Q4 2015 and held it in 11 quarters.
  • Sheaff Brock Investment Advisors's Theriva Biologics position peaked at $195K in Q4 2015.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Sheaff Brock Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.